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ABSTRACT 
 
 
 Children with medulloblastoma suffer a poor prognosis, but currently available 
treatments have toxic effects and short half-lives, necessitating the development of more 
effective tumor-selective therapies.  The cytokine Tumor Necrosis Factor (TNF)-related 
apoptosis-inducing ligand (TRAIL), a pro-apoptotic protein, has shown efficacy as a targeted 
anti-tumor agent that spares normal cells; however, some tumor cells remain resistant to its 
effects.  The purpose of this project was to investigate the use of a combined therapy of TRAIL 
plus histone deacetylase inhibitor MS-275 to make medulloblastoma cells sensitive to TRAIL-
mediated apoptosis.  Mesenchymal stem cells (MSCs) have been used to deliver apoptotic 
proteins to tumor cells due to their high affinity for those cells, but a description of how 
therapeutic MSCs interact with meduloblastoma type tumor cells is lacking.  In this study, a 
human MSC cell line expressing TRAIL (hMSC-S-TRAIL) previously engineered in the Shah 
lab was used to investigate its therapeutic effect in vitro on a moderately TRAIL-resistant 
medulloblastoma cell line, DAOY, in the presence or absence of MS-275.  The results indicate 
that DAOY cells respond to hMSC-delivered TRAIL, and that MS-275 strongly enhances this 
effect.  Real-time bioluminescent imaging also showed that a medulloblastoma cell line 
engineered to express firefly luciferase can survive and grow in an intracranial xenograft model 
in mice, allowing this model to be used in the future for in vivo studies. 
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BACKGROUND 
 
 
Medulloblastoma 
 Medulloblastoma is an especially malignant brain tumor that accounts for 30% of all 
pediatric brain tumors (Polkinghorn and Tarbell, 2007).  Its peak incidence is at 7 years of age, 
with a slightly higher incidence in boys than girls.  Patients often present with morning vomiting, 
ataxia, headaches, and a solid mass in the posterior fossa that can be imaged (Polkinghorn and 
Tarbell, 2007).  Medulloblastomas tend to disseminate through the subarachnoid space; up to 
32% of patients demonstrate cerebrospinal fluid (CSF) metastasis (Fouladi et al., 1999).  Current 
treatments for medulloblastoma – primarily surgery, chemotherapy, and cerebrospinal irradiation 
– result in a 5-year survival prognosis of about 60%.  Patients who benefit from chemotherapy 
and radiation experience drastic side effects, including cognitive impairment, psychiatric 
disorders, skeletal growth retardation, liver and kidney toxicity, and endocrine dysfunctions 
(Polkinghorn and Tarbell, 2007).  These side effects are due to the non-specific nature of chemo- 
and radiotherapy, thus it is vital to find a cancer-selective therapy that avoids damaging healthy 
tissues. 
 
 
TRAIL 
 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of 
the TNF cytokine family (Wiley et al., 1995).  It is a pro-apoptotic molecule that targets tumor 
cells and spares normal cells both in vitro and in vivo (Walczak et al., 1999).  Figure 1 shows the 
mechanism of TRAIL-mediated apoptosis (Seckulic et al., 2008).  TRAIL interacts with Death 
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Receptors (DR and DR) 4 and 5 on the cell surface – the presence of these receptors in 
transformed cells, such as tumor cells, and their absence in normal cells, makes the cells 
respectively sensitive and resistant to TRAIL-mediated apoptosis (Ashkenazi and Dixit, 1999).  
TRAIL binding to DR4 or DR5 results in a caspase cascade: activation of initiator caspases 8 and 
10 leads to cleavage of effector caspase 3, for an extrinsic apoptotic pathway, and/or Bid in an 
intrinsic pathway (Shah et al., 2004; Carew et al., 2008; Sekulic et al., 2008).  
 
 
Figure 1:  Induction of Cell Death by TRAIL.  Diagram 
shows the activation of extrinsic and intrinsic pro-apoptotic 
caspase cascades following TRAIL binding to death receptors 
DR4/5. (Figure 3 from Sekulic et al., 2008) 
 
 
TRAIL and Cancer 
 Due to TRAIL’s pro-apoptotic activity, it has been tested for potential anti-tumor therapy.  
Treatment with TRAIL has shown tumor-reducing results for both glioblastoma and 
medulloblastoma tumors in vitro and in mice (Shah et al., 2004; Shah et al., 2005a; Tsurushima 
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et al., 2007; Hingtgen et al., 2008).  This approach seems promising, but about half of the tumor 
lines are resistant to TRAIL-mediated apoptosis, so finding a mechanism of sensitizing these 
tumors to TRAIL has been a focus of the Shah Lab. 
 
 
Histone Deacetylases and Cancer 
 One attractive mechanism for making tumors more susceptible to TRAIL is histone 
deacetylase (HDAC) inhibition.  Histones are positively-charged proteins that help organize 
DNA into nucleosomes, which can be made more or less transcripionally active through 
acetylation or deacetylation, respectively.  Acetylation contributes a negative charge to the 
positively-charged histones, thereby neutralizing the histones and releasing their attraction to 
negatively-charged DNA.  This causes the nucleosome to relax allowing transcriptional enzymes 
to bind, so that section of DNA becomes more transcriptionally active.  Histone deacetylation 
has the opposite effect – it causes the histones to tighten, leading to less transcriptionally-active 
genes.  HDACs acting on tumor suppressor genes lower their expression levels, which may allow 
for tumorigenesis.  In fact, several HDACs have been shown to be over-expressed in various 
tumor types (Carew et al., 2008). 
 
 Histone deacetylase inhibitors (HDACi) are synthetic drugs that inhibit HDAC activity, 
and can be divided into the following classic categories: hydroxamic acids, cyclic tetrapeptides, 
benzamides, electrophilic ketones, and aliphatic acid compounds.  These compounds act on 
HDAC classes I and II by binding to a zinc-containing catalytic domain common to members of 
the two classes (Drummond et al., 2005).  HDACi’s have been widely demonstrated to activate 
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cell death pathways in various cancer models (Saito et al., 1999; Rosato et al., 2003; Richon, 
2006; Xu et al., 2007).  Furthermore, cell death initiated by some HDACi’s has been shown to 
occur via the TRAIL-mediated apoptosis pathway, with increased expression for DR5 and other 
death receptors and ligands (Rosato et al., 2003; Carew et al., 2008). Figure 2 is a schematic of 
the cellular processes in which HDAC inhibitors are involved (Carew et al., 2008). Of note is 
HDACi activation of both the intrinsic and extrinsic pathways leading to apoptosis. 
 
 
Figure 2: Mechanisms of HDAC Inhibitor-Induced Cell 
Death.  (Figure 1 from Carew et al., 2008; red and blue ovals not 
present in original, and they are used to highlight the role of 
HDACi’s in apoptosis pathways) 
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MS-275 
 The HDACi MS-275, a benzamide derivative, is potent against class I HDACs, and can 
inhibit cell proliferation (cytostatic activity) and induce apoptosis (cytotoxic activity) in acute 
myeloid leukaemia cells through arrest at the G1 phase, upregulation of p21, and downregulation 
of cyclins (Rosato et al., 2003; Nebbioso et al., 2005).  When administered to mice in 
micromolar concentrations, MS-275 has exhibited brain region-specificity (Simonini et al., 
2005).  In medulloblastoma lines specifically, MS-275 has been demonstrated to sensitize the 
cells to TRAIL by reactivating DR4 and upregulating caspase-8 (Aguilera et al., 2009; Häcker et 
al., 2009).  Another study reported activation of caspases 3 and 9 as part of MS-275’s 
mechanism of action (Sonnemann et al., 2006).  All four of these agents (DR4 and caspases 3, 8, 
and 9) are key players in the pro-apoptotic pathway.  A 2009 study has previously shown that 
MS-275 treatment of cells sensitizes TRAIL-resistant medulloblastoma cells to TRAIL by 
upregulation of DR4.  Figure 3 shows evidence of this sensitization – decreased metabolic 
activity after combined MS-275 and TRAIL therapy on a TRAIL-resistant line (Aguilera et al., 
2009).   
While MS-275 appears to be potent and region-specific in vivo, soluble TRAIL so far has 
been rather ineffective in vivo; it is cleared quickly following systemic administration, and so it 
requires a large dose to effect tumor regression (Hingtgen et al., 2008).  
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Figure 3: Sensitization to TRAIL After HDACi (MS-275) Treatment in DAOY 
Cells.  “Daoy cells were treated with either a sub-toxic concentration of MS-275 
(0.625 uM) alone or in conjunction with various concentrations of soluble TRAIL 
(2.5–10 ng) for 24, 48 and 72 h.  Cells were treated with TRAIL alone (2.5–10 ng) as 
controls. Decrease in metabolic activity was determined using MTT assays, and 
normalized using absorbance obtained using extracts from untreated cells.” (Figure 
4A from Aguilera et al., 2009) 
 
 
Cell-Based Therapy 
 The Shah lab overcame the obstacle of soluble TRAIL’s rapid clearance by investigating 
cell-based therapies.  Neural stem cells (NSC) have grown popular as neuro-oncotherapeutic 
agents because of their specific tropism to and therapeutic effect against malignant tumor cells 
(Aboody et al., 2001; Heese et al., 2005; Gutova et al., 2008).  The Shah lab previously 
engineered a secretable form of TRAIL, S-TRAIL, that has been shown to be more effective than 
native TRAIL at inducing apoptosis and tumor regression through use of the bystander effect 
(Shah et al., 2004; Shah et al., 2005b).  In a 2005 study, Shah and colleagues engineered neural 
precursor cells (NPC) to express S-TRAIL, and demonstrated using bioluminescent imaging that 
NPC-S-TRAIL cells migrate towards, and subsequently inhibit the growth of, established 
gliomas in mice when implanted in close vicinity to the tumor (Shah et al., 2005a).  A 2010 
study from the Shah lab used engineered NSC-S-TRAIL cells to eradicate intracranial 
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glioblastoma.  Both the cancer and stem cells were imageable through use of bioluminescent 
markers; Figure 4 shows NSC-S-TRAIL’s anti-tumor effect when co-implanted with 
glioblastoma in mice (Hingtgen et al., 2010).   
 
 
Figure 4: Treatment of Intracranial Glioblastomas with NSC-S-
TRAIL Results in Significant Inhibition of Tumor Growth.  
“mNSC were transduced with control vector or SRLOL2TR, and 
implanted with Gli36 EGFRvIII-FD intracranially in mice. Mice 
were injected with D-Luciferin, and FLuc imaging was performed to 
visualize changes in glioma on days 1, 3, 6, 9, 13, and 21 post-
implantation. Representative images and summary data are shown. C 
= Control; T = SRLOL2TR..” (Figure 5C from Hingtgen et al., 2010) 
 
 Looking forward to human trials using this approach, NSCs would pose a problem 
because allogenic transplantation runs the risk of immunologic rejection, and procuring and 
delivering them would require additional invasive procedures in the brain for the patient 
(Nakamizo et al., 2005).  Bone marrow contains a number of stem cell types, including 
mesenchymal stem cells (MSC) that have been shown to exhibit properties similar to neural 
precursor cells, most notably tropism towards gliomas in vivo (Nakamizo et al., 2005).  
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Furthermore, cultured MSCs engineered to secrete Interleukin-2 demonstrated the same tropism 
towards gliomas as non-therapeutic bone marrow-derived MSCs and induced a therapeutic effect 
(Nakamura et al., 2004).  A recent study engineered human MSCs to express S-TRAIL to treat 
gliomas in a mouse xenograft model and observed effective reduction in tumor growth (Menon 
et al., 2009).  Tropism towards tumors and the ability to be genetically engineered make MSCs 
an attractive therapeutic delivery vehicle for cancers in the brain.  This method has great 
potential for human studies since harvesting bone marrow to isolate MSCs is a far less invasive 
and potentially damaging procedure than the isolation of NSCs, and MSCs from the patient 
would allow for autologous transplantation. 
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PROJECT PURPOSE 
 
 
As discussed in the Background, TRAIL is a pro-apoptotic protein that has shown some 
efficacy as an anti-tumor agent for various brain cancers, while sparing normal cells.  Because 
some tumor cells appear to be resistant to its effects, researchers are investigating co-therapies 
such as histone deacetylase inhibitor MS-275 to help make resistant tumor cells responsive to 
TRAIL.  Systemic administration of TRAIL in mouse models of cancer has proven to be 
inefficient, so mesenchymal stem cells (MSCs) are an attractive vehicle to deliver the therapeutic 
protein, given their demonstrated affinity for tumor cells, including glioblastoma in vivo.  A 
thorough investigation of how MSCs and medulloblastoma-type tumors interact is lacking.  In 
this project, we used a human MSC cell line expressing TRAIL (hMSC-TRAIL) previously 
engineered in the Shah lab to investigate its therapeutic effect on a moderately TRAIL-resistant 
medulloblastoma cell line in vitro.  We further sought to sensitize this line to TRAIL-mediated 
apoptosis using the HDAC inhibitor MS-275.  Finally, in a step towards an in vivo study, we 
used real-time bioluminescent imaging to demonstrate that a medulloblastoma cell line 
expressing firefly luciferase can survive and grow in an intracranial xenograft model in mice. 
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METHODS 
 
 
 
Cell Culture 
The Daoy-Fluc medulloblastoma cell line was kindly given to us by Nabil Ahmed 
(Department of Pediatrics at Baylor College of Medicine, Houston, TX).  Cells were cultured in 
Dulbecco’s Modified Eagle’s medium (DMEM; GIBCO, Grand Island, NY) supplemented with 
10% fetal calf serum (Valley Biomedical Inc., Winchester, VA), sodium bicarbonate (Lonza, 
Switzerland), GlutaMAX-I (GIBCO, Grand Island, NY), nonessential amino acids (Cellgro, 
Manassas, VA), and sodium pyruvate (Cellgro, Manassas, VA).  
The hMSC-S-TRAIL cell line was created via lentiviral transduction of human 
mesenchymal stem cells, transduced weekly by Shawn Hingtgen (MNIL at MGH, Boston, MA).  
Cells were cultured in Alpha-MEM (GIBCO, Grand Island, NY) supplemented with 10% fetal 
calf serum (Valley Biomedical Inc., Winchester, VA), L-glutamine (GIBCO, Grand Island, NY), 
and penicillin/streptomycin (GIBCO, Grand Island, NY). 
Cell incubations were performed in a humidified atmosphere with 5% CO2 at 37°C. 
 
 
Luciferase Assay System 
Daoy cell survival in a given experimental condition was measured by the activity of 
expressed firefly luciferase (Fluc).  An equal amount of D-luciferin substrate was administered to 
each well in each treatment group (see Co-Culture methods below), and luminescence was read 
with a luminometer, using 0.5 seconds integration per well. 
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Medulloblastoma and Stem Cell Co-Culture Experiments 
For co-culture experiments without MS-275, varying numbers of DAOY-Fluc cells (1k, 
2k, 3k, 4k, 5k) were plated in a 96-well format, and after 24 hours either plain hMSC or hMSC-
S-TRAIL cells were added to the culture, in hMSC medium, and incubated for an additional 24 
hours.  A luciferase assay was performed to measure live DAOYs.  For sensitization 
experiments, DAOY-Fluc cells were plated in a 96-well format, and after 24 hours were pre-
treated for 24 hours with 2.5 μM MS-275 (Cayman Chemical, Ann Arbor, MI) in DAOY 
medium.  Then, either plain hMSC or hMSC-S-TRAIL cells were added to the culture in hMSC 
medium, and incubated for another 24 hours, followed by a luciferase assay to measure live 
DAOYs. 
 
 
Intracranial Cell Implantations and In Vivo Imaging 
To assay the survival of medulloblastoma cells in vivo, DAOY-Fluc cells were harvested 
at 80-90% confluency and implanted stereotactically into the left frontal lobe of Nude mice 
brains (6*10
5
/mouse, in 4 μl of DMEM, n=3) (2.2 mm lateral from bregma, on the cranial suture, 
2.5 mm ventral from dura).  Mice were imaged for Fluc activity on days 1, 7, 14, 21, 28, and 35 
after implantations.  Before imaging, mice were injected intraperitoneally with D-luciferin (1.0 
mg/mouse) and imaged after 10 minutes.  Coronal brain sections (25 um) from day 28 after 
implantation were stained by a standard H&E staining procedure.  All in vivo procedures were 
approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital.  
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RESULTS 
 
 
This project focused on sensitizing TRAIL-resistant medulloblastomas to stem cell-
delivered TRAIL using the histone deacetylase inhibitor MS-275.  In order to test a TRAIL-
resistant line for induced TRAIL-sensitivity, resistance or sensitivity to TRAIL-mediated 
apoptosis first had to be verified in several medulloblastoma cell lines.  Seven established human 
medulloblastoma lines (DAOY, R300, UW426, D283, D458, R262, and UW473) were incubated 
with varied concentrations of S-TRAIL for 24 hours and analyzed for viability (CellTiter-Glo, 
Promega; Figure 5; Simone Wanningen, unpublished data).  DAOY, D283, D458, and UW473 
lines were determined to be resistant to concentrations of S-TRAIL ranging from 0.5-5.0 ug/mL, 
whereas R300, UW426 and R262 were sensitive to these concentrations of S-TRAIL (Simone 
Wanningen, personal communication).  Based on these data, the DAOY line was chosen for 
further investigation to study its sensitivity to TRAIL mediated apoptosis with and without MS-
275 pre-treatment . 
 
 
Figure 5: Varying Sensitivity to TRAIL in Several Medulloblastoma Cell Lines. 
Seven cell lines were treated with concentrations of S-TRAIL (0, 0.5, 1.0, 2.5, and 
5.0 ug/mL) for 24 hours.  Cell viability was analyzed using the CellTiter-Glo system, 
and normalized to that of untreated cells.  (Simone Wanningen, unpublished data) 
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Previous experiments in our laboratory with MS-275 used soluble S-TRAIL to establish 
that the HDACi does indeed sensitize DAOY cells.  Cells were pre-treated with MS-275 for 24 
hours, then treated with S-TRAIL, and finally analyzed for viability and activity of caspases 3 
and 7 (Simone Wanningen, personal communication).  Figure 6 shows evidence of the 
sensitization: decreasing viability (Fig. 6A) and increasing activity of caspases 3 and 7 (Fig. 6B) 
in DAOYs after combined MS-275 and TRAIL therapy (Simone Wanningen, unpublished data).  
Cell viability was measured by a quantitative luminescence assays using an ATP-dependent 
luminescent reagent (CellTiter-Glo, Promega) and Caspase 3/7 activity was determined with a 
caspase 3/7-activatable DEVD-aminoluciferin (Caspase-Glo, Promega).  
 
 
Figure 6: Sensitization to TRAIL After HDACi (MS-275) Treatment in DAOY 
Cells. (A) Viability analysis using the CellTiter-Glo system on DAOY cells treated 
with 0.5 ug/mL TRAIL for 24 hours (red), 0.625 uM and 1.25 uM MS-275 for 48 
hours in combinations with TRAIL (blue), and untreated DAOY cells (gray).  (B) 
Caspase 3 and 7 analysis using the Caspase-Glo system on DAOY cells treated with 
0.5 ug/mL TRAIL for 24 hours (red), 1.25 uM MS-275 for 48 hours in combinations 
with TRAIL (blue), and untreated DAOY cells (gray).  (Simone Wanningen, 
unpublished data) 
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 After choosing the fairly TRAIL-resistant DAOY line, and showing that DAOYs can 
become sensitized to TRAIL with MS-275 pre-treatment, we received a DAOY line that was 
engineered to express firefly luciferase (DAOY-Fluc).  Figure 7 demonstrates that luminescence 
increases with increasing numbers of DAOY-Fluc cells after the addition of D-luciferin 
substrate.  Fig. 7 also features a trendline whose R
2
 value is 0.9996, indicating that it is a strong 
correlation between cell number and luminescence.  Luciferase can only be expressed in live 
cells, thus a luciferase assay can be used to measure the relative number of live cells by 
normalizing the data from the treatment group to that of control groups.  The DAOY-Fluc cell 
line, and consequently the luciferase assay system, was used in all experiments thereafter. 
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Figure 7: Luminescence from Luciferase Expressing DAOYs Can Be 
Used to Measure Relative Live Cell Number.  DAOY cells in increasing 
numbers (5k, 10k, 20k, 50k, 100k, 200k) in a 96 well plate were treated 
with equal amounts of D-luciferin substrate.  The plate was read with a 
luminometer, using 0.5 sec integration/well.  R
2
 = 0.9996. 
 
 
 19 
 A major focus of this project was stem-cell-based therapy.  In order to study the effect of 
stem cells on medulloblastoma cells, DAOY cells were co-cultured for 24 hours with either 
human mesenchymal stem cells (hMSC) previously engineered to express S-TRAIL, or with 
plain hMSCs.  The luciferase signal from DAOYs in each group was measured using a luciferase 
assay (Figure 8).  While the ratio of MSCs to DAOY cells did not appear to have a strong effect 
in Fig. 8A, either normal hMSCs or hMSC-TRAIL equally slightly lowered DAOY cell survival.  
Overall, there does not appear to be much additional killing by hMSC-S-TRAIL over plain 
hMSC.  This is in line with previous results indicating that DAOYs are resistant to TRAIL.  
Thus, the delivery of TRAIL by MSCs does not appear to have a strong effect.   
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Figure 8:  Survival of DAOY Cells Co-Cultured With Therapeutic and Plain 
hMSCs.  Increasing numbers of DAOY cells were co-cultured for 24 hours with a 
constant number of plain hMSC (purple) or hMSC-S-TRAIL (tan). The plate was 
read with a luminometer, with 0.5 sec integration/well. Luminescence of treated 
DAOYs was normalized to that of untreated cells (blue). 
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 In order to sensitize the DAOYs to hMSC-delivered TRAIL, DAOYs were pre-treated 
for 24 hours with 2.5 uM MS-275, and then either plain or TRAIL-expressing hMSCs were 
added to the treated DAOY cells in a co-culture experimental set up (Figure 9).  In contrast to 
the TRAIL experiments of Fig. 8, there was significantly more killing by the combination 
therapy than either monotherapy.  Of note is that DAOYs treated with either hMSC-S-TRAIL 
(second histobar) or MS-275 and plain hMSCs (third histobar) were killed more than in previous 
experiments with TRAIL- and MS-275-treated DAOY cells (Aguilera et al., 2009; Simone 
Wanningen, unpublished data).   
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Figure 9: MS-275 Sensitizes DAOY Cells to hMSC-TRAIL.  DAOY cells were 
either untreated or pre-treated with 2.5 uM MS-275 for 24 hours, followed by 
incubation with plain hMSC or hMSC-S-TRAIL for 24 hours. The plate was read with 
a luminometer, with 0.5 sec integration/well. Luminescence of treated DAOYs was 
normalized to that of untreated cells cultured with plain hMSCs. 
 
 
 Finally, in an initial step towards performing in vivo experiments with MS-275 and 
hMSC-TRAIL, DAOY-Fluc cells were implanted intracranially in nude mice to show that the 
cells will form growing tumors.  Tumor growth was monitored over five weeks using 
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bioluminescent imaging following systemic administration of 1.0 mg of D-luciferin substrate 
(Figure 10, A and B). Brain sections from day 28 post-implantation were stained with 
hemotoxylin and eosin (Fig. 10, C and D).  DAOY-Fluc cells were actually implanted one week 
before the implantation described above, on the opposite side of the sagittal suture, but 
bioluminescent imaging on days 1 and 6 after that implantation indicated a decreasing signal in 
all animals (data not shown), so the cells were thought to have dispersed instead of forming a 
tumor.  However, on day 1 in Fig. 10B, both tumors were detectable and so, were allowed to 
continue growing.  Despite the confusion, the experiment’s overall outcome is the same: 
modified human medulloblstoma cells (DAOY-Fluc) cells can survive and form growing tumors 
in a xenograft model in nude mice. 
 
 
Figure 10:  Human DAOY-Fluc Cells Can Survive and Grow in Nude Mice.  (A) 
Luminescence Fluc readings from DAOY-Fluc cells 1, 7, 14, 21, 28, 35 days after 
intracranial implantations, n=3.  Bars indicate +/- SD.  (B) Representative images 
from one mouse 1, 7, 14, 21, 28, 35 days after DAOY-Fluc implantation.  (C) 
Photomicrograph of H&E-stained brain sections from day 28, 10x.  (D) 20x. 
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DISCUSSION 
 
 
 
 In this study, we investigated hMSC-TRAIL’s therapeutic effect on a moderately TRAIL-
resistant DAOY medulloblastoma cell line in vitro, in the presence or absence of histone 
deacetylase inhibitor MS-275 as a co-inducer of tumor cell apoptosis.  The data show that 
DAOY cells respond about equally to normal hMSCs and the hMSC-delivered TRAIL, and that 
MS-275 enhances the apoptotic effect.  We further sought to test a mouse model for future in 
vivo experiments, and have demonstrated that DAOY-Fluc cells are capable of surviving and 
growing into tumors after intracranial implantation using data from bioluminescent imaging.  
 Stem cell-mediated therapy is emerging as a strategy to effectively deliver molecular 
therapies, like TRAIL, in the brain.  They offer one interesting feature: tropism towards 
malignant tumor cells (Aboody et al., 2001; Nakamura et al., 2004; Heese et al., 2005; Shah et 
al., 2005a; Gutova et al., 2008; Sasportas et al., 2009).  A number of studies have used neural 
stem cells as an effective vehicle to deliver therapies to both glioma- and medulloblastoma-type 
tumors.  However, looking forward to human trials using NSCs would pose serious problems – 
complicated surgeries to extract and reimplant them, or immuno-suppression due to an allogenic 
transplant issues.  Mesenchymal stem cells (MSCs) harvested from bone marrow are relatively 
easy to obtain and allow for autologous transplantation, making them an attractive option for a 
cell-based therapy for medulloblastoma. 
 TRAIL has demonstrated effectiveness as a tumor-selective cytotoxic agent both in 
soluble form and when secreted by engineered stem cells in vitro and in vivo (Shah et al., 2004; 
Shah et al., 2005a; Tsurushima et al., 2007; Hingtgen et al., 2008; Sasportas et al., 2009; 
Hingtgen et al., 2010).  However, many tumor cell lines remain resistant to TRAIL-mediated 
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apoptosis, and currently many studies seek to sensitize these lines to TRAIL.  One seemingly 
effective synthetic agent is the histone deacetylase inhibitor MS-275, which has been shown to 
sensitize medulloblastoma cells to TRAIL by reactivating death receptor-4 (DR4), and 
upregulating apoptotic caspases 3, 8, and 9, all of which are major players in the pro-apoptotic 
pathway (Sonnemann et al., 2006; Aguilera et al., 2009; Häcker et al., 2009).   
Previous results from our lab have confirmed that pre-treating DAOY cells, a TRAIL-
resistant medulloblastoma cell line, with MS-275 as part of a combination therapy with soluble 
TRAIL sensitizes them to TRAIL-mediated apoptosis (Fig. 6; Simone Wanningen, unpublished 
data).  Although results from this study show that MS-275 treatment enhances the effect of 
mesenchymal stem cell-delivered S-TRAIL, the data conflicted as to whether DAOY cells are 
sensitive to hMSC-delivered S-TRAIL (Fig. 8 and 9A).  This may be due to the fact that the 
hMSC-S-TRAIL were  engineered every week to express S-TRAIL and the two experiments 
were performed in different weeks.  The hMSC-S-TRAIL line was created by lentiviral 
transduction, which has a somewhat cytostatic effect on the cells; the hMSCs stop proliferating 
post-infection and eventually die, thus limiting the number of TRAIL-secreting cells that can be 
harvested from one infection.  The discrepancy in killing by hMSC-S-TRAIL may be a factor of 
varied TRAIL-expression due to differences in transduction quality and efficiency from week to 
week.  Because of this variability and cytostatic effect, it may eventually be useful to develop an 
alternative method of TRAIL delivery to stem cells using vaccinia or adenovirus, or to select for 
stem cells permanently expressing TRAIL.  
Additionally, the MSCs themselves, both plain and therapeutic, seem to have an effect on 
DAOY cells.  Data from Fig. 8A indicates that co-cultured cells proliferated less in the presence 
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of either plain or TRAIL-secreting hMSCs than when left to grow alone.  This may be due to 
various chemokines normally produced by the hMSCs. 
Intracranial implantation of DAOY-Fluc cells was successful both times, despite initial 
confusion.  Tumor growth monitored in Fig. 10, A and B, progressed as expected, although 
review by more-experienced lab members revealed that the bioluminescent signal from DAOY-
Fluc tumors is much weaker than the signal from other comparably-sized Fluc-expressing tumors 
previously used in the lab.  Nonetheless, the tumors are imageable, and this DAOY-Fluc line can 
be used to assess the therapeutic efficacy of MS-275 and TRAIL in near future MS-275 
experiments in mice. 
Future in vivo experiments will build off this last experiment and follow the general 
structure of the co-culture experiments.  First, successful implantation of DAOY-Fluc cells will 
be confirmed by the presence of an established tumor.  MS-275 will then be administered 
systemically to treatment groups.  After some time, therapeutic and diagnostic stem cells will 
then be implanted intratumorally.  Tumor growth will be monitored with bioluminescent imaging 
at all steps of the experiment.  Ideally, the stem cells will be imageable as well, perhaps with the 
additional transduction of Renilla luciferase (Rluc), which utilizes a different substrate than D-
luciferin, and thus can also be monitored during the experiment. 
Other experiments such as long term fate of tumor cells, MSC, MS-275 pharmacokinetics 
could be performed to obtain data for a human trial in medulloblastomas patients.  In the long 
term we envision a resection model where the tumor mass is removed and the patient’s own 
therapeutically engineered MSCs are implanted in the resulting cavity during the same surgical 
event.  This would be minimally invasive and would allow the MSCs to kill both residual and 
invasive tumor cells.  
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